Prof Tim Brümmendorf speaks to ecancer at the virtual ASH 2020 meeting about the final 5-year results of the Bfore trial which looked at bosutinib versus imatinib for newly diagnosed chronic phase CML.
He explains that it has previously been presented that bosutinib showed superior major molecular response after 12 months with this study aiming to demonstrate whether or not bosutinib would be show deeper responses and be superior after 5 years.
Prof Brümmendorf reports that this superiority with deeper responses was demonstrated, with MR4.5, MR4 and MR3 all yielding better results under bosutinib.
This program is funded in part via an independent grant from AbbVie. ecancer is editorially independent and there is no influence over content.